Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
Healthcare
$26.75 +0.27%
+$0.09 today
- Market cap
- $1.93B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
52W Low $19.07High $56.05
Volume 1.05M
Average 1.18M
Balance Sheet
Inspect the capital base behind the business.
Assets
$734.73M
FY 2025 · Annual
+12.1% YoYLiabilities
$130.21M
FY 2025 · Annual
+65.8% YoYEquity
$604.52M
FY 2025 · Annual
+4.7% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 79.67M | 43.46M | 45.68M | 92.65M | 354.73M |
| Short-term Investments | 0 | 71.19M | 115.04M | 548.21M | 359.86M |
| Net Receivables | 0 | 0 | 0 | 3.77M | 3.29M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 480K | 719K | 3.22M | 913K | 2.54M |
| Total Current Assets | 82.54M | 125.7M | 172.02M | 651.22M | 728.88M |
| Property, Plant & Equipment (Net) | 0 | 5.22M | 3.04M | 4.33M | 1.92M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 867K | 58K | 11K | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 344K | 455K | 471K | 131K | 3.93M |
| Total Non-current Assets | 1.21M | 5.74M | 3.52M | 4.46M | 5.85M |
| Total Assets | 83.75M | 131.44M | 175.55M | 655.68M | 734.73M |
| Account Payables | 1.39M | 11.99M | 11.12M | 7.67M | 21.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 377K | 0 | 4.82M | 0 | 1.37M |
| Total Current Liabilities | 7.69M | 25.6M | 22.3M | 25.37M | 53.46M |
| Long-term Debt | 4.92M | 24.81M | 49.88M | 50.69M | 74.84M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.54M | 286K | 286K | 0 | 0 |
| Total Non-current Liabilities | 6.47M | 28.93M | 51.56M | 53.16M | 76.76M |
| Total Liabilities | 14.16M | 54.53M | 73.86M | 78.53M | 130.21M |
| Common Stock | 21K | 28K | 44K | 64K | 71K |
| Retained Earnings | (124.06M) | (213.11M) | (309.1M) | (461.25M) | (760.87M) |
| Accumulated OCI | (0) | (224K) | 251K | 393K | 786K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 69.59M | 76.91M | 101.69M | 577.16M | 604.52M |
| Total Debt | 4.92M | 31.29M | 53.71M | 54.64M | 77.31M |
| Net Debt | (74.75M) | (12.17M) | 8.03M | (38.01M) | (277.42M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $48.9M |
| Short-term Investments | $450.3M |
| Other Current | $28.3M |
| Total Current Assets | $527.5M |
| PP&E (Net) | $1.7M |
| Other Non-current | $3.8M |
| Total Non-current Assets | $5.5M |
| Total Assets | $533.0M |
Analysis
Selected assets total $533.0M for Latest. The largest visible component is Short-term Investments at $450.3M, about 84.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 8-K | Current report | Sep 15, 2026 |
How much cash does VERA have?
Vera Therapeutics, Inc. (VERA) reported $354.73M in cash and equivalents in fiscal 2025.
How much debt does VERA carry?
Vera Therapeutics, Inc. (VERA) reported $77.31M of total debt, with net debt of -$277.42M.
Continue the stock analysis
Jump to another research area for this company.